VERA
NASDAQVera Therapeutics Inc.
Price$27.90+0.08 (+0.29%)
01:30 PM07:45 PM
News · 26 weeks47-57%
2026-04-192026-10-11
Mix2090d
- Insider8(40%)
- Other7(35%)
- SEC Filings3(15%)
- Leadership1(5%)
- Analyst1(5%)
Latest news
25 items- ANALYSTLeerink Partners initiated coverage on Vera Therapeutics with a new price targetLeerink Partners initiated coverage of Vera Therapeutics with a rating of Market Perform and set a new price target of $34.00
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 16,700 shares of Class A common stock and restricted stock units (RSUs) underlying 8,350 shares of Class A common stock to five (5) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on September 29, 2026 has a
- PRVera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy (IgAN) will be a featured late-breaking oral presentation during the opening plenary session and also a late-breaking research poster. In addition, interim results from the adult IgAN and primary membranous nephropathy (pMN) cohorts in PIONEER, a Phase 2 basket trial of atacicept in multiple glomerular diseases, will be
- INSIDERPRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $684,500 worth of shares (18,500 units at $37.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- SECVera Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA NephropathyTRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease progression benefits.Favorable safety profile, and generally comparable to placebo. Strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks. Plan to submit supplemental BLA to the U.S. Food and Drug Administration (FDA) for full approval in Q4 2026. BRISBANE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that TRUTAKNA met all prespecified end
- INSIDERSVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R exercised 5,000 shares at a strike of $3.94, increasing direct ownership by 7% to 80,754 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERPRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $649,642 worth of shares (18,500 units at $35.12) as part of a pre-agreed trading plan (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each s
- PRVera Therapeutics to Participate at Upcoming Investor ConferencesBRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Cantor Global Healthcare Conference 2026Format: Fireside Chat and 1x1 investor meetings Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=39555950&checkCompany=1&checkEmail=1&checkName=1Date: Thursday, September 10, 2026Time: 8:00am ETLocation: New York, NY Morgan Stanley 24th Annual Global Healthcare Conference Format: Fireside Chat and
- INSIDERAmendment: PRESIDENT AND CEO Fordyce Marshall exercised 46,250 shares at a strike of $2.90 and sold $1,956,187 worth of shares (46,250 units at $42.30) as part of a pre-agreed trading plan (SEC Form 4)4/A - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERAmendment: PRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $701,769 worth of shares (18,500 units at $37.93) as part of a pre-agreed trading plan (SEC Form 4)4/A - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERAmendment: PRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $679,747 worth of shares (18,500 units at $36.74) as part of a pre-agreed trading plan (SEC Form 4)4/A - Vera Therapeutics, Inc. (0001831828) (Issuer)
- SECSEC Form 10-Q filed by Vera Therapeutics Inc.10-Q - Vera Therapeutics, Inc. (0001831828) (Filer)
- SECVera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial ResultsTRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026.Anticipated supplemental Biologics License Application (sBLA) submission to the FDA – expected in Q4 2026. BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today reported its business highlights and financial results for the quarter ended June 30, 2026. "The accelerated approval and
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 63,011 shares of Class A common stock and restricted stock units (RSUs) underlying 44,987 shares of Class A common stock to Nancy Bowman, M.D., Ph.D., Vera’s new Chief Regulatory Officer, under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan), and on August 4, 2026, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purch
- SECSEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)
- INSIDERChief Regulatory Officer Boman Nancy Lee was granted 44,987 shares (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 3 filed by new insider Boman Nancy Lee3 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock
- INSIDERPRESIDENT AND CEO Fordyce Marshall sold $1,956,187 worth of shares (46,250 units at $42.30) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 151,994 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- SECVera Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William TurnerBRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position. William Turner, current Chief Regulatory Officer of Vera Therapeutics, is planning to retire and transition to the role of Strategic Advisor in the third quarter of this year after a successful tenure at the company, including the recent accelerated approval of Vera Therapeutics’ first therapy in IgA nephropathy (IgAN), TRUTAKNA™ (atacicept-vymj). Nancy Boman, M.D., Ph.D., will succeed Mr. Turner as Chief Regulatory Officer of Vera Therapeutics. "On behalf of the Board of Director
- FDAFDA Approval for TRUTAKNA issued to VERA THERAPEUTICS INC.Submission status for VERA THERAPEUTICS INC.'s drug TRUTAKNA (ORIG-1) with active ingredient ATACIEPT-VYMJ has changed to 'Approval' on 07/07/2026. Application Category: BLA, Application Number: 761486, Application Classification:
VERA FAQ
7 questionsWhat does Vera Therapeutics Inc. do?
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco...Where does VERA stock trade?
Vera Therapeutics Inc. (VERA) is listed on NASDAQ.What sector and industry is VERA in?
Vera Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Vera Therapeutics Inc. go public?
Vera Therapeutics Inc. (VERA) completed its IPO in 2021.What are analysts saying about VERA?
Vera Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform with a $3400.00 price target on 2026-10-12. Recent price targets range from $3400.00 to $4900.00.What companies are similar to VERA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VERA side-by-side with any of them on Quantisnow.How can I track VERA on Quantisnow?
Quantisnow aggregates Vera Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VERA to receive live email and push alerts on every new disclosure.